Martingale Asset Management’s Immunovant IMVT Stock Holding History

Martingale Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$462K	Buy	+18,607	New	+$482K	0.01%	659
2023 Q2	–	Sell	-21,605	Closed	-$335K	–	841
2023 Q1	$335K	Sell	21,605 -18,105	-46%	-$314K	0.01%	691
2022 Q4	$705K	Sell	39,710 -30,428	-43%	-$383K	0.01%	554
2022 Q3	$392K	Buy	70,138 +74	+0.1%	+$362	0.01%	665
2022 Q2	$274K	Buy	70,064 +13	+0%	+$56	0.01%	751
2022 Q1	$386K	Buy	70,051 +8,200	+13%	+$51.1K	0.01%	685
2021 Q4	$527K	Buy	61,851 +2,900	+5%	+$23.9K	0.01%	636
2021 Q3	$513K	Buy	58,951 +39,430	+202%	+$356K	0.01%	666
2021 Q2	$207K	Buy	+19,521	New	+$273K	﹤0.01%	799

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Martingale Asset Management's IMVT Position: Q1 2026 in Review

Martingale Asset Management opened a new position in Immunovant (IMVT) in Q1 2026: 18,607 shares worth $462K. The stake represents 0.01% of the portfolio and ranks #659 among its holdings. This is a return to the name: Martingale Asset Management previously reported a position in IMVT as recently as Q1 2023.

Martingale Asset Management first reported a position in IMVT in Q2 2021 and has held it in 9 quarters since. The position peaked at $705K in Q4 2022. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Martingale Asset Management held 18,607 shares of Immunovant worth $462K as of Q1 2026.
Immunovant was a new Martingale Asset Management position in Q1 2026.
Immunovant made up 0.01% of Martingale Asset Management's portfolio in Q1 2026, its #659 holding.
Martingale Asset Management first reported a position in Immunovant in Q2 2021 and has held it in 9 quarters since.
Martingale Asset Management's Immunovant position peaked at $705K in Q4 2022.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.